Viatris rises after quarterly results beat

Shares of generic drugmaker Viatris VTRS.O rise 1.1% to $8.69 premarket

VTRS posts Q1 adj profit of 50 cents per share, compared with analysts' estimate of 49 cents per share, according to data compiled by LSEG

Company reports Q1 revenue of $3.25 billion vs estimates of $3.23 billion

Company also maintains 2025 revenue forecast to be between $13.5 billion and $14 billion, below analysts' estimates of $14.27 billion

Co expects 2025 adj profit between $2.12 and $2.26 per share, compared with estimates of $2.59 per share

Separately, VTRS also said its fast-acting form of generic pain drug meloxicam met the main goals of two late-stage studies and a lower dose version of its birth control patch, called Xulane, also met all the main goals of a late-stage study

Up to last close, stock has fallen 30.9% YTD